Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells

被引:0
|
作者
Motwani, M [1 ]
Li, XK [1 ]
Schwartz, GK [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Gastrointestinal Oncol Res Lab, New York, NY 10021 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Defects in cell cycle checkpoints can lead to chromosome abnormality, aneuploidy, and genomic instability, all of which can contribute to tumorigenesis. Recent studies and data presented in this study indicate that cells with compromised G(1) checkpoint endoreduplicate and become polyploid in response to microtubule inhibitors, Previous studies have shown that polyploid cells are unstable and lose chromosomes randomly to give aneuploidy, In this study, we show that endoreduplication and polyploidation can be prevented by inhibiting the cyclin-dependent kinases (Cdks) by flavopiridol, a synthetic flavone presently undergoing phase II clinical trials. In our initial studies, we treated MCF-7 cells with paclitaxel, which results in the arrest of cells in G(1) with 4n DNA content (pseudo G(1)), This was coincident with increased p53 and p21 protein expression and decreased cyclin E/Cdk2 kinase activity. In contrast, G(1) checkpoint-compromised MDA-MB-468 (p53-/- and pRb-/-) and p21-/- HCT116 do not arrest in the pseudo G(1) state after exposure to microtubule inhibitors and enter in the S phase with 4n DNA content. More than 60% of MDA-MB-468 cells accumulate with >4n DNA content after 72 h of nocodazole treatment. The MPM-2 labeling showed that 8n cells also undergo mitosis, These cells display deregulated and persistent activation of cyclin E/Cdk2 and cyclin B1/cdc2 kinase activity. Administration of flavopiridol after mitotic block results in the arrest of cells in the pseudo G(1) state and the dramatic decrease in cells containing >4n DNA content in MDA-MB-468 cells. The cyclin E/Cdk2 and cyclin B1/cdc2 kinase activities remained low after exit from mitosis, Furthermore, pRb was hypophosphorylated after the addition of flavopiridol in p21-deficient HCT116 cells, indicating the arrest of cells at the pseudo G(1) state, Based on these studies, we propose that flavopiridol preserves the genomic stability by preventing endoreduplication and polyploidy and thus has the potential to be used as a chemopreventive agent to prevent the occurrence of neoplasia.
引用
收藏
页码:924 / 932
页数:9
相关论文
共 50 条
  • [41] SENSITIVITY OF HUMAN MENINGIOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02
    Le Rhun, E.
    von Achenbach, C.
    Sahm, F.
    Wang, S. S.
    Neidert, M. C.
    Rushing, E.
    Lawhon, T.
    Schneider, H.
    von Deimling, A.
    Weller, M.
    NEURO-ONCOLOGY, 2019, 21 : 17 - 17
  • [42] Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol
    Nelson, PJ
    D'Agati, VD
    Gries, JM
    Suarez, JR
    Gelman, IH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) : 921 - 929
  • [43] Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
    von Achenbach, Caroline
    Le Rhun, Emilie
    Sahm, Felix
    Wang, Sophie S.
    Sievers, Philipp
    Neidert, Marian C.
    Rushing, Elisabeth J.
    Lawhon, Tracy
    Schneider, Hannah
    von Deimling, Andreas
    Weller, Michael
    TRANSLATIONAL ONCOLOGY, 2020, 13 (12):
  • [44] Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study
    Stadler, WM
    Vogelzang, NJ
    Amato, R
    Sosman, J
    Taber, D
    Liebowitz, D
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 371 - 375
  • [45] Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo
    Wirger, A
    Perabo, FGE
    Burgemeister, S
    Haase, L
    Schmidt, DH
    Doehn, C
    Mueller, SC
    Jocham, D
    ANTICANCER RESEARCH, 2005, 25 (6B) : 4341 - 4347
  • [46] Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
    Schwartz, GK
    Ilson, D
    Saltz, L
    O'Reilly, E
    Tong, W
    Maslak, P
    Werner, J
    Perkins, P
    Stoltz, M
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) : 1985 - 1992
  • [47] Uptake and metabolism of the cyclin-dependent kinase inhibitor flavopiridol in cultured mouse osteoblasts:: Implications on therapy.
    Hoffmann, O
    Hagenauer, B
    Haslmayer, P
    Thalhammer, T
    Jäger, W
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S407 - S407
  • [48] The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
    Tanaka, Tomohito
    Terai, Yoshito
    Ashihara, Keisuke
    Fujiwara, Satoe
    Tanaka, Yoshimichi
    Sasaki, Hiroshi
    Tsunetoh, Satoshi
    Ohmichi, Masahide
    PLOS ONE, 2017, 12 (05):
  • [49] Lack of imprinting of three human cyclin-dependent kinase inhibitor genes
    Cost, GJ
    Thompson, JS
    Reichard, BA
    Lee, JY
    Feinberg, AP
    CANCER RESEARCH, 1997, 57 (05) : 926 - 929
  • [50] Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus
    Taylor, SL
    Kinchington, PR
    Brooks, A
    Moffat, JF
    JOURNAL OF VIROLOGY, 2004, 78 (06) : 2853 - 2862